- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
David Hughes, PharmD, BCOP | Authors
Expert Commentary on the Product Profile of Tepotinib
November 14, 2021
In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.
David Hughes, PharmD, and Jessica Freydman, PharmD, Discuss the Mechanism of Action of Tepotinib for MET exon 14+ NSCLC
October 28, 2021
A clinical pharmacy manager and a pharmacy resident detail the unique mechanism of action of tepotinib for metastatic non–small cell lung cancer with mutations in MET exon 14.